Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

143.72 -1.09 (-0.75%)

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

78 79 Next >

Gilead Announces Positive Results From Trodelvy-Keytruda Combo Study For Breast Cancer: But Retail’s Unmoved ↗

April 21, 2025

Triple-negative breast cancer accounts for approximately 15% of all breast cancers and has a higher chance of recurrence.

Via Stocktwits

Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer

April 21, 2025

From Gilead Sciences, Inc.

Via Business Wire

Why Quality Investors May Find GILEAD SCIENCES INC (NASDAQ:GILD) Attractive. ↗

April 19, 2025

A fundamental analysis of (NASDAQ:GILD) shows GILEAD SCIENCES INC (NASDAQ:GILD) may be suited for quality investing, we'll explore why in this article.

Via Chartmill

2 High-Yielding ETFs Retirees Can Safely Build Their Portfolios Around ↗

April 17, 2025

Via The Motley Fool

Time 100 Most Influential People Includes Elon Musk, Mark Zuckerberg, Alex Karp And More Public Company CEOs ↗

April 16, 2025

The Time 100 list of the most influential people in the world includes Elon Musk, Mark Zuckerberg and several other CEOs of publicly traded companies.

Via Benzinga

Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction ↗

April 16, 2025

Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating...

Via Benzinga

Topics Government

3 Reasons GILD is Risky and 1 Stock to Buy Instead

April 15, 2025

In a sliding market, Gilead Sciences has defied the odds, trading up to $106.42 per share. Its 24% gain since October 2024 has outpaced the S&P 500’s 6.9% drop. This was partly due to its solid...

Via StockStory

Topics Stocks

Is Iovance Biotherapeutics a Millionaire-Maker? ↗

April 14, 2025

Via The Motley Fool

Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies ↗

April 11, 2025

Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.

Via Benzinga

Topics Government World Trade

Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025

April 10, 2025

From Gilead Sciences, Inc.

Via Business Wire

S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash ↗

April 10, 2025

Here's why the 90-day tariffs delay doesn't help pharmaceutical companies.

Via Investor's Business Daily

Topics Government Stocks World Trade

Rule Breaker Investing: Essays From Yesterday, Vol. 7 ↗

April 10, 2025

Via The Motley Fool

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline ↗

April 09, 2025

Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.

Via Benzinga

Topics Government Supply Chain World Trade

Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗

April 09, 2025

The US market session of Wednesday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today.

Via Chartmill

Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports ↗

April 09, 2025

Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports.

Via Investor's Business Daily

Topics Government Stocks World Trade

2 Top Dividend Stocks That Could Set You Up for Life ↗

April 09, 2025

Via The Motley Fool

Topics Government Initial Public Offering Intellectual Property

Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks ↗

April 04, 2025

Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

Via Benzinga

Topics Government World Trade

Amazon, Alphabet, KLA And A Health Care Stock On CNBC's 'Final Trades' ↗

April 03, 2025

Via Benzinga

Intel's New CEO Outlines Recovery Strategy. Wall Street Remain Cautious. ↗

April 01, 2025

Intel's new CEO, Lip-Bu Tan, offered his strategy for turning around the troubled chipmaker in a speech late Monday. But Intel stock fell.

Via Investor's Business Daily

2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

April 01, 2025

JPMorgan's upgrade on Gilead sparks bullish sentiment for the healthcare sector—here's why stocks like Pfizer and Hims & Hers are promising opportunities.

Via MarketBeat

1 Healthcare Stock to Target This Week and 2 to Turn Down

March 31, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the...

Via StockStory

Topics Stocks

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today ↗

March 27, 2025

Via Benzinga

What Analysts Are Saying About Gilead Sciences Stock ↗

March 27, 2025

Via Benzinga

A Closer Look at Gilead Sciences's Options Market Dynamics ↗

March 27, 2025

Via Benzinga

Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares? ↗

March 27, 2025

The FDA is due to make an approval decision in mid-September for a key product from the top pharma company.

Via Investor's Business Daily

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗

March 21, 2025

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.

Via Benzinga

No Quick Fix For This Market ↗

March 23, 2025

Despite the pullback, we have found numerous opportunities which we discuss in this video using technical analysis.

Via Talk Markets

Topics Stocks / Equities

Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

March 21, 2025

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its...

Via StockStory

Topics Artificial Intelligence

Which S&P500 stocks are gapping on Thursday? ↗

March 20, 2025

Let's have a look at the S&P500 gap up and gap down stocks in today's session.

Via Chartmill

Gilead Stock Wobbles On Federal HIV Funding Cut Buzz, But Retail And Analysts Stay Unfazed ↗

March 20, 2025

The company has a portfolio of HIV prevention treatments such as Biktarvy and Descovy.

Via Stocktwits

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

78 79 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.